INDEX

Abbreviated new drug application (ANDA), 13
Acquired immunodeficiency syndrome (AIDS), 11
Active pharmaceutical ingredient (API), 121, 172
Acute lymphoblastic leukemia (ALL), 143
Acute myeloid leukemia (AML), 154
Adverse event reporting blood-related deaths, 73
development, review and approval regulatory approaches, 68
five-day MDR reporting, 68–72
Agreement Meeting, 56
AIDS. See Acquired immunodeficiency syndrome (AIDS)
ALL. See Acute lymphoblastic leukemia (ALL)
Allergenic extracts, 10
AML. See Acute myeloid leukemia (AML)
ANDA. See Abbreviated new drug application (ANDA)
Antibiotic bone cement drug-active device combination, 127
Antihypertensive combinations, 160
API. See Active pharmaceutical ingredient (API)
Application fees combination product, 46–47
Approval adverse event reporting, 68–73
CGMP, 59–66
clinical investigation and premarket review requirements, 11–14
detailed regulatory approaches, 5–74
device malfunction reporting, 68
drugs, biological products, and medical devices, 11–14
Approval (Continued)
FDA information resources, 15
intercenter agreements, 18
PDUFA, 44–49
PMOA, 20–29
postmarketing, 67–74
regulatory interactions, 50–58
RFD process, 34–43
strategic regulatory considerations, 31–33
Aspirin, 131
Available waivers
combination product, 46–47
BAC. See Bioanalytical chemistry (BAC) methods
BCS. See Biopharmaceutics Classification Scheme (BCS)
Bexxar (tositumomab), 155, 156
CDP, 157–159
Bioanalytical chemistry (BAC) methods, 90
Biolimus A9, 133
Biological products
alert reporting, 73
clinical investigation and premarket review requirements, 11–14
definitions, 6
intended use, 30
postmarket event reporting requirements, 70–72
reporting, 70–72
Biological Response Modifiers Advisory Committee (BRMAC), 156
Biologic license application (BLA), 12
fees waiver/reduction, 46, 47
supplement Pegasys, 139
Biomarkers
converting into IVD, 147
BioMatrix, 133
Biopharmaceutics Classification Scheme (BCS), 162
BLA. See Biologic license application (BLA)
Blood-related deaths
development, review and approval regulatory approaches, 73
BRMAC. See Biological Response Modifiers Advisory Committee (BRMAC)
CAPA. See Corrective action/preventative action (CAPA) program
CBER. See Center for Biologics Evaluation and Research (CBER)
CDER. See Center for Drug Evaluation and Research (CDER)
CDP. See Combination drug product (CDP)
CDRH. See Center for Devices and Radiological Health (CDRH)
Cellular products, 10
Center for Biologics Evaluation and Research (CBER), 1–2, 7, 8, 10, 27, 28, 115
informal consultations, 52
intercenter agreements, 18
Center for Devices and Radiological Health (CDRH), 2, 7, 8–9, 11, 26, 29, 30, 116
agreement meeting, 54
Day-100 meeting, 55
determination meeting, 54
informal consultations, 52, 57
informal pre-IDE meetings, 52
intercenter agreements, 18
Center for Drug Evaluation and Research (CDER), 1, 7, 8, 26–27, 115–116
informal consultations, 52
intercenter agreements, 18
Center for Food Safety and Applied Nutrition (CFSAN), 7
Center for Veterinary Medicine (CVM), 8
CFSAN. See Center for Food Safety and Applied Nutrition (CFSAN)

CGMP. See Current Good Manufacturing Practice (CGMP)

Chemistry, manufacturing, and controls (CMC), 114, 172
bench testing, 180
CDP regulatory cross-mapping guidance, 180
controls regulatory strategy, 172
device component requirements, 179
device exemption, 174
drug component requirements, 178
drug exemption, 174
early development, 180
OCP, 172
RCPD, 175–176
regulatory oversight, 173
regulatory strategy, 171–200
review requirements, 177
RFD, 172
stability, 180
sterilization, 179

Chemotherapeutic drug for targeted cancer treatment
jurisdictional assignment, 27
MOA/PMOA, 26–27

Chlorpromazine, 164

Circulatory System Devices Panel Meeting, 131

Clinical development
CDP, 113–165
Clinical investigation requirements
drugs, biological products, and medical devices, 11–14

Clinical safety reporting
CDP, 115
clinical development of drug-delivery system, 116–121

Clopidogrel, 131

CMC. See Chemistry, manufacturing, and controls (CMC)

Collaborative review, 42

Combination drug product (CDP), 78
Bexxar, 157–159
biomarker development, 146
carcinogenicity studies, 102
clinical development, 113–165
of drug-active device, 127–133
of drug-delivery system, 116–121
clinical trial design issues, 147–148
co-development of drugs, 144–145
combination product with novel delivery route, 119

CombinatoRx with combination therapy, 163–164
co-packaged, 134–135
CYP450 isozymes, 86–87

DES case study, 128–131
drug-biologic combination products, 153–159
drug-drug combinations, 160–163
drug-in vitro diagnostics, 140–150
co-development, 147–148
drug metabolism recommendations, 89–91
efficacy improvement routes, 117
excipient safety, 120
excretion, 87

Exubera case study, 121–126
FDA guidance, 149

FDC efficacy studies, 162
formulation changes during clinical development, 121
genotoxicity studies, 102, 103–104

Herceptin and Hercep Test, 150

human physiology during development, 120

immune system reactions during development, 120
infusion pump impact on pharmacodynamic effects, 119
inherent delivery site sensitivity, 119

interferon and ribavirin for hepatitis C, 135
Combination drug product (Continued)
with marketed drugs
and more than one NME, 91
multiple, 89–90, 98–102
and single NME, 83, 91,
102–103
with more than one NME, 83,
104–107
Mylotarg, 154–156
new delivery device drug product
advantages, 117–119
new DES product changing
scene, 132
nonclinical recommendations,
77–111
noninjection bioavailability for
peptides and proteins, 118
pharmacokinetics, 84–91
pharmacology, 79–83, 113–164
postapproval clinical safety
reporting, 115–116
protein binding, 86
reproductive toxicology
studies, 102
retrospective changes in drug
labeling to incorporate genetic
tests, 143
route-dependent pharmaceutical
metabolic profile, 119
route of administration, 85–86
safety with multiple marketed drugs,
80–82
streamlined regulatory process
possible, 117
tissue distribution, 86
toxicology, 92–107
bridging study, 107
in vitro diagnostics, 144–145
Combination products
adverse event reporting, 68
application fees and available
waivers or reductions,
46–47
assigning to FDA center, 25
CGMP, 59–66
clinical pharmacology and
development
drug-biologic combination
products, 153–159
drug-in vitro diagnostic
combination products,
144–145
prospective co-development of
drugs, 144–145
in vitro diagnostics, 144–145
definitions, 2, 16
development, 1–4
examples, 17
Good Manufacturing Practice
provisions, 61
ICA, 18
identifying product regulatory
path, 33
intended use, 30
PDUFA, 44–49
postmarketing, 67–74
regulatory background, 16
regulatory interactions, 50–58
regulatory review, 1–4
RFD process, 34–43
strategic regulatory considerations,
31–33
CombinatoRx, 163
Controls information
drug components, 178–179
Copegus, 138–139
Coronary drug-eluting stents
drug-active device
combination, 127
Corrective action/preventative action
(CAPA) program, 179
CoStar stent, 132, 133
COURAGE study, 134
Current Good Manufacturing Practice
(CGMP), 18, 59–61, 177
combination products, 59–66
cross mapping guidance, 182–197
operating manufacturing control
system, 61
regulation, 61
INDEX

CVM. See Center for Veterinary Medicine (CVM)
Cypher, 129

Day-100 meeting, 55, 57
DES. See Drug-eluting stent (DES)
Determination Meeting, 56

Development
adverse event reporting, 68–73
CGMP, 59–66
clinical investigation, 11–14
combination products, 1–4
detailed regulatory approaches, 5–74
device malfunction reporting, 68
drugs, biological products, and medical devices, 11–14
FDA information resources, 15
intercenter agreements, 18
PDUFA, 44–49
PMOA, 20–29
postmarketing, 67–73
premarket review requirements, 11–14
regulatory interactions, 50–58
RFD process, 34–43
strategic regulatory considerations, 31–33

Device
definition, 6
development, review and approval, 68
malfunction reporting, 68
QS regulation requirement, 63–65
regulatory approaches, 68
systems approach to quality, 63–65

Dipyrimadole, 164

Drug
candidates
acute toxicity profile, 93
carcinogenicity studies, 94
genotoxicity assessments, 94
immunogenicity studies, 95
interactions, 93
local tolerance, 95
metabolites, 95
reproductive and developmental toxicity, 95
route of administration, 93
toxicology profiles, 93
CGMP requirement, 63–65
clinical investigation and premarket review requirements, 11–14
combinations defined, 79
definition, 6
labeling to incorporate genetic tests, 143
product alert reporting, 73
reporting postmarket event reporting requirements, 70–72

Drug-active device combination, 127
antibiotic bone cement, 127
coronary drug-eluting stents, 127

Drug-biologic combination, 154
coopackaged, 135

Drug-delivery system combinations, 117

Drug-drug combination, 160

Drug-eluting stent (DES)
case study, 128–131
CDP, 128–131
PMOA, 128–129
working toward PMA, 133

Drug-in vitro diagnostic combination, 141

EGFR. See Epidermal growth factor receptor (EGFR)
Endeavor, 132, 133
Epidermal growth factor receptor (EGFR), 146
Erbitux, 144, 146
Evaluation activities
21 CFR CGMP regulations, 199
Everolimus, 133
Exubera (Pfizer’s inhaled insulin)
case study, 121–126
CDP, 121–126
long-term safety data, 123–124
marketing approval, 121
postmarketing commitments, 126
regulatory status, 121
Exubera (Continued)
smoking, 124–125
vs. subcutaneous insulin, 123–124

Fast Track designation, 51, 56
FDA. See Food and Drug Administration (FDA)
FDAMA. See Food and Drug Administration Modernization Act (FDAMA)
FDCs. See Fixed-dose combinations (FDCs)
Federal Food, Drug and Cosmetic Act (FD&C Act)
device defined, 6
drug defined, 6
Final notice of completion, 56
Fixed-dose combinations (FDCs), 160
categories, 161
Follow up, 58–59
Food and Drug Administration (FDA), 1
form 483, Inspectional Observations, 74
guidance
drug-test co-development concept paper, 150
genetic tests, 150
industry, 149–150
pharmacogenetic tests, 150
meetings for combination products, 50–58
OCP, 19
organization and jurisdiction, 7–19
Food and Drug Administration Modernization Act (FDAMA), 56

Gemtuzumab, 154
Gene therapy products, 10
Genetic tests
drug labeling, 143

Genomics and Personalized Medicine Act of 1006 (senate Bill 2833), 142
Genous stent, 132
Gleevec, 144, 146
GLP. See Good Laboratory Practice (GLP) Regulations
GMP, See Good Manufacturing Practice (GMP)
Good Laboratory Practice (GLP) Regulations, 90
Good Manufacturing Practice (GMP), 44
provisions, 61
Regulation 21 CFR 210, 211, 182
Regulation 21 CFR 820, 182
single-entity combination products, 61
Guidance documents, 15–16

Helicobacter pylori detection test, 141
Hepatitis C
CDP, 135
Hercetp Test, 152
CDP, 150
marketing approval, 151
PMOA, 151
regulatory status, 151
Hercetpin (Her2/neu, trastuzumab), 144, 146, 150, 151, 152
CDP, 150
marketing approval, 151
PMOA, 151
regulatory status, 151
HIV/AIDS cocktails, 160
HIV test kits, 11

ICA. See Intercenter Agreement (ICA)
ICH. See International Conference on Harmonisation (ICH)
IDE. See Investigational device exemption (IDE)
Implantable device with local chemotherapeutic drug
Mode of action (MOA), 3, 21–23, 26–27
Monoclonal antibody
linked to cytotoxic drug, 154
CDP, 154–156
regulatory status, 155
linked to radioisotope, 155, 156, 157–159
for targeted cancer treatment
jurisdictional assignment, 27
MOA/PMOA, 26–27
6-MP. See 6-mercaptopurine (6-MP)
Mylotarg, 154
CDP, 154–156
regulatory status, 155
National Cancer Institute Cooperative Breast Cancer Tissue Resource, 152
National Center for Toxicological Research (NCTR), 8
National Institutes of Health (NIH), 9
NCE. See Novel chemical entities (NCE)
NCTR. See National Center for Toxicological Research (NCTR)
NDA. See New drug application (NDA)
New drug application (NDA), 12, 43, 117
fees waiver/reduction, 46, 47
NIH. See National Institutes of Health (NIH)
NME. See Novel molecular entities (NME)
NOAEL. See No observable adverse effect level (NOAEL)
NOC. See Notice of completion (NOC)
Nonclinical recommendations for successful characterization and development of CDP, 77–112
Noninjection bioavailability
CDP, 118
for peptides and proteins, 118
No observable adverse effect level (NOAEL), 99
Notice of completion (NOC), 56
Not substantially equivalent (NSE), 13–14
Novel chemical entities (NCE), 77
Novel molecular entities (NME)
CDP, 104–107
with marketed drugs, 83, 91, 102–103
local tolerance assessments, 107
pharmacokinetic/toxicokinetic and drug metabolism activities, 88
pharmacology and safety pharmacology, 81–82
recommended nonclinical safety or toxicology activities, 96–98
NSE. See Not substantially equivalent (NSE)
Obama, Barack, 142
OCP. See Office of Combination Products (OCP)
ODAC. See Oncologic Drugs Advisory Committee (ODAC)
Office of Combination Products (OCP), 2, 114
CMC, 172
development, review and approval, 19
informal consultations, 52
regulatory approaches, 19
Office of Regulatory Affairs (ORA), 9
Oncologic Drugs Advisory Committee (ODAC), 156
Ondansetron hydrochloride, 118
ORA. See Office of Regulatory Affairs (ORA)
OTC. See Over-the-counter (OTC)
Over-the-counter (OTC), 13
Paclitaxel (Taxol), 133, 164
Paclitaxel-eluting system (Taxusw Express2), 129
PathVysion, 153
PDP. See Product Development Protocol (PDP)
PDUF. See Prescription Drug User Fee Act (PDUFA)
PEG. See Polyethylene glycol (PEG)
Pegasys, 138–139
BLA supplement, 139
QOL, 139
Pegintron, 136, 137–138
co-labeled with ribavirin, 136
regulatory status, 136
Pentamidine, 164
Peptides
noninjection bioavailability, 118
Personalized medicine, 141
Pfizer’s inhaled insulin. See Exubera (Pfizer’s inhaled insulin)
PMA. See Premarket approval (PMA)
PMOA. See Primary mode of action (PMOA)
Polyethylene glycol (PEG), 137
Postmarketing
commitments, 126
development, review and approval regulatory approaches, 67–74
event reporting requirements, 69–72
Exubera, 126
Prednisolone, 164
Premarket approval (PMA), 15
fees waiver/reduction, 46, 47
supplement, 49–50
Premarket review requirements
drugs, biological products, and medical devices, 11–14
Prescription Drug User Fee Act (PDUFA)
combination products, 44–50
fees waiver/reduction, 46, 47
meetings, 51
type A meeting, 53
type B meeting, 53
type C meeting, 53
Primary mode of action (PMOA), 3, 21–23, 26–27
development, review and approval regulatory approaches, 20–29
intended use, 30–31
Product
definition, 6
development and regulatory review, 1–4
development meetings, 50–51
Product Development Protocol (PDP), 56
PROTECT trial, 133–134
Proteins
noninjection bioavailability, 118
Public Health Service Act
(Sect. 351), 1
biological product defined, 7
Quality by design (QbD), 179
Quality of life (QOL)
Rapamycin derivative, 133
RCPD. See Regulatory Compliant Product Development (RCPD)
Rebetol, 137
Rebetron, 136, 137
Reduction fees
combination product, 46–47
Regulatory approaches
adverse event reporting, 68–73
blood-related deaths, 73
CGMP, 59–66
clinical investigation requirements, 11–14
definitions, 6
development, review and approval, 5–74
Regulatory approaches (Continued)
device malfunction reporting, 68
drug and biological product alert reporting, 73
drugs, biological products, and medical devices, 11–14
FDA information resources, 15
five-day MDR reporting, 68–72
intended use, 30
intercenter agreements, 18
OCP, 19
PDUFA, 44–49
PMOA, 20–29
postmarketing, 67–74
premarket review requirements, 11–14
regulatory interactions, 50–58
RFD process, 34–43
strategic regulatory considerations, 31–33
Regulatory Compliant Product Development (RCPD), 171, 175–176
Regulatory considerations
combination products, 31–33
Regulatory review
combination products, 1–4
Request for designation (RFD), 21, 114, 173
CMC, 172
combination products process, 33–42
process, 35
required content, 37–40
writing guidance, 173
Resources
21 CFR CGMP regulations, 198
Review
adverse event reporting, 68–73
CGMP, 59–66
clinical investigation and premarket review requirements, 11–14
CMC requirements, 177
detailed regulatory approaches, 5–74
device malfunction reporting, 68
drugs, biological products, and medical devices, 11–14
FDA information resources, 15
intercenter agreements, 18
PDUFA, 44–49
PMOA, 20–29
postmarketing, 67–74
regulatory interactions, 50–58
RFD process, 34–43
strategic regulatory considerations, 31–33
RFD. See Request for designation (RFD)
Rheumatoid arthritis, 164
Ribavirin
for hepatitis C, 135
Risk management standard
ISO, 62
Scaffold seeded with autologous cells
for organ replacement
jurisdictional assignment, 27
MOA/PMOA, 27
Section 505 of the Food, Drug and Cosmetic Act, 1
Senate Bill 2833, 142
Single-entity combination products
Good Manufacturing Practice provisions, 61
SIRIUS study, 130
Sirolimus-eluting coronary stent system (Cypher), 129
6-mercaptopurine (6-MP), 143
Smoking
Exubera, 124–125
Spinal fusion device coated
MOA/PMOA, 26
with therapeutic protein, 26
Strategic plan, 57–58
Strategic regulatory considerations
combination products, 31–33
 Systems approach
  device QS regulation requirement, 63–65
  drug CGMP requirement, 63–65
  to quality, 63–65

 Tarceva, 146
 Targeted therapies, 146
 Taxol, 133, 164
 Taxus Express Paclitaxel-Eluting Coronary Stent System, 130, 132
 TAXUS IV study, 130
 Taxus Liberte, 133
 Taxusw Express2, 129
 Therapeutic protein
  jurisdictional assignment, 26
 Thiopurine methyltransferase (TMTP), 143–144
 TMTP. See Thiopurine methyltransferase (TMTP)
 Tositumomab, 155, 156
 CDP, 157–159
 Transdermal patches, 117

 Trastuzumab. See Herceptin (Her2/neu, trastuzumab)
 Trust, 58
 User fees
  combination products, 44–49

 Vaccine, 10
 Vertebroplasty implant
  with extended-release analgesic, 29–30
  jurisdictional assignment, 30
  MOA/PMOA, 29
 Voluntary Genomic Data Submission (VGDS), 147

 Writing, 58

 Xience, 132, 133
 Zensana, 118
 Zevalin, 159
 Zofran (ondansetron hydrochloride), 118
 Zotarolimus, 133